nach oben

Breast Cancer Research and Treatment

Erschienen in:

12.07.2018 | Letter to the Editor

Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy

verfasst von: Mattia Rediti, Carlo Messina

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

We read with great interest the meta-analysis by Poggio et al. regarding neoadjuvant platinum-based chemotherapy (PBC) in triple negative breast cancer (TNBC) [1]. PBC significantly increased the pathological complete response (pCR) rate in TNBC patients (from 37.0 to 52.1%; OR 1.96, 95% CI 1.46–2.62, P < 0.001) at the cost of a higher risk of grade 3/4 haematological toxicities. However, PBC was not associated with a meaningful increase in pCR rate among the 96 germline BRCA (gBRCA) mutants included. …

Poggio F, Bruzzone M, Ceppi M et al. (2018) Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. https://doi.org/10.1093/annonc/mdy127 CrossRefPubMed

Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767CrossRef

Bareche Y, Venet D, Ignatiadis M et al. (2018) Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 29(4):895–902CrossRef

Telli ML, Timms KM, Reid J et al. (2016) Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 22(15):3764–73CrossRef

Telli ML, Metzger O, Timms KM et al. (2018) Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin ± veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. J Clin Oncol 36:519 (suppl; abstr 519)CrossRef

Titel: Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy
verfasst von: Mattia Rediti
Carlo Messina
Publikationsdatum: 12.07.2018
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4885-9

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy

Excerpt

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen

Pro-inflammatory cytokines and growth factors in human milk: an exploratory analysis of racial differences to inform breast cancer etiology

Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study

Population-based validation of the National Cancer Comprehensive Network recommendations for breast cancer staging

Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema

Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie